Movement Disorders is a lot more than Parkinson.
Great session on #tics (by @TMPringsheim), #Huntington’s (by Mark Guttman), #tremor (by Mandar Jog), and #dystonia (by Davide Martino).
#CMDS2023

Are we ready for a biological definition (or classification?) of #parkinson disease?

Tony Lang says yes
Michael Schlossmacher says no

It was fun to ‘moderate’ (really!) this debate
#CMDS2023

Debate: would you offer subcutaneous #levodopa BEFORE other more invasive options?
The majority at #CMDS2023 says yes!
Drs Bouchard and Sarna emphasized the easy access but also the high rate of discontinuation.

.@copn_rpco: you’re on stage now! (Presented by Oury Monchi)
#CMDS2023

Brilliant talk by Ron Postuma: RBD is for now the only marker of prodromal #parkinson able to let us enrol enough subjects for a
disease modifying trial.
#CMDS2023

Robert Chen (@RobertC21093233) on neurophysiology of #parkinson: beta recording and aDBS is an elegant example of how knowing informs treatments.
Followed by panel discussion.
#CMDS2023

Jon Stoessl on the role of neuro-imaging in #parkinson.
‘What we know is a drop, what we don’t know is an ocean’
#CMDS2023
@ParkinsonCanada

Lorraine Kalia (@kalialabs) on the knowns and unknowns of alpha-synuclein, from diagnosis to treatment.
Including caveats on commercially accessible seeding assays for the general population…
#CMDS2023
@ParkinsonCanada

The 2nd annual meeting of Canadian Movement Disorders Society (in partnership with @ParkinsonCanada) just kicked off!
Stay tuned for more
#CMDS2023